We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Agilon Health (AGL) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Agilon Health (AGL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Agilon Health is a member of the Medical sector. This group includes 884 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AGL's full-year earnings has moved 62.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AGL has gained about 395.3% so far this year. Meanwhile, stocks in the Medical group have lost about 6% on average. This means that Agilon Health is outperforming the sector as a whole this year.
Another stock in the Medical sector, Humacyte, Inc. (HUMA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.6%.
In Humacyte, Inc.'s case, the consensus EPS estimate for the current year increased 28% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Agilon Health is a member of the Medical Services industry, which includes 62 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 11.6% so far this year, so AGL is performing better in this area.
Humacyte, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 430-stock industry is ranked #142. The industry has moved -0.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Agilon Health and Humacyte, Inc. as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Agilon Health (AGL) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Agilon Health (AGL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Agilon Health is a member of the Medical sector. This group includes 884 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AGL's full-year earnings has moved 62.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AGL has gained about 395.3% so far this year. Meanwhile, stocks in the Medical group have lost about 6% on average. This means that Agilon Health is outperforming the sector as a whole this year.
Another stock in the Medical sector, Humacyte, Inc. (HUMA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.6%.
In Humacyte, Inc.'s case, the consensus EPS estimate for the current year increased 28% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Agilon Health is a member of the Medical Services industry, which includes 62 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 11.6% so far this year, so AGL is performing better in this area.
Humacyte, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 430-stock industry is ranked #142. The industry has moved -0.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Agilon Health and Humacyte, Inc. as they attempt to continue their solid performance.